Liu Jie, Wang Huailing, Luo Qiang, Qiu Shuqi, He Zhendan, Liu Zhigang, Yang Liteng, Liu Xiaoyu, Sun Xizhuo
The Third Affiliated Hospital of Shenzhen University, Shenzhen University Shenzhen 518020 China
School of Medicine, Shenzhen University Shenzhen 518060 China
RSC Adv. 2020 Feb 27;10(14):8377-8384. doi: 10.1039/c9ra10400c. eCollection 2020 Feb 24.
LingZhi () has been used as a therapeutic agent for decades, but the antitumor potency of LingZhi oligopeptides (LZOs) was not well explored. In current study, ten novel LZO amino acid sequences were identified, and anticancer potency was evaluated. We found that LZO-3 [EGHGF] significantly triggered A549 cell apoptosis mitochondrial dysregulation, as evidenced by caspases activation, mitochondrial membrane potential collapse, Bcl-2/Bax ratio alteration, and cytochrome c release. Further, the down-regulation of Trx/TrxR reductase and the improvement of the MDM2/p53 state also contributed to the LZO-3-induced cell apoptosis. Notably, our findings provide evidence for the novel potency of LZOs, which could be developed as promising chemotherapeutic agents against lung cancer.
灵芝已被用作治疗药物数十年,但灵芝寡肽(LZOs)的抗肿瘤效力尚未得到充分研究。在当前研究中,鉴定了10种新的LZOs氨基酸序列,并评估了其抗癌效力。我们发现LZO-3 [EGHGF]显著触发A549细胞凋亡和线粒体失调,这通过半胱天冬酶激活、线粒体膜电位崩溃、Bcl-2/Bax比率改变和细胞色素c释放得以证明。此外,Trx/TrxR还原酶的下调和MDM2/p53状态的改善也促成了LZO-3诱导的细胞凋亡。值得注意的是,我们的研究结果为LZOs的新效力提供了证据,其可被开发为有前景的抗肺癌化疗药物。